Stroke. 2010 Apr;41(4):805-9. doi: 10.1161/STROKEAHA.109.574137. Epub 2010 Feb 18.
Telestroke has been effective in the management of acute ischemic stroke. This study characterizes and compares stroke specialist (SS) and emergency physician (EP) perceptions of telestroke and identifies barriers preventing increased implementation.
A survey was developed and distributed nationwide to 382 SSs through an online survey system and in paper form to 226 EPs attending the 2008 American College of Emergency Physicians national conference.
Stroke specialists perceived themselves to be more knowledgeable about telemedicine and telestroke (P<0.001 and P=0.010, respectively). A large majority of physicians in both specialties either strongly agreed or agreed that telestroke will reduce geographical differences in stroke management and that it is superior to telephone consultation. EPs perceived patient preference (P<0.001), recombinant tissue plasminogen activator side effects (P<0.001), level of technology (P=0.005), and recombinant tissue plasminogen activator not the standard of care (P<0.001) to be more significant obstacles to increased implementation of telestroke than SSs. However, SSs found increased personal work to be a greater barrier than EPs (P<0.001).
SSs and EPs report positive beliefs regarding telestroke; however, perceived obstacles exist to implementation. Differences between barriers perceived by EPs and SSs need to be addressed to enhance acute ischemic stroke treatment.
远程卒中在急性缺血性卒中的管理中已经有效。本研究对卒中专家(SS)和急诊医师(EP)对远程卒中的看法进行了描述和比较,并确定了阻碍其推广应用的障碍。
通过在线调查系统和 2008 年美国急诊医师学会全国会议上的 226 名 EP 以纸质形式向全国 382 名 SS 分发了一份调查问卷。
卒中专家认为自己对远程医疗和远程卒中的了解更深入(P<0.001 和 P=0.010)。两个专业的大多数医生都强烈同意或同意远程卒中将减少卒中管理中的地域差异,而且它优于电话咨询。EP 认为患者偏好(P<0.001)、重组组织型纤溶酶原激活剂的副作用(P<0.001)、技术水平(P=0.005)和重组组织型纤溶酶原激活剂不是标准治疗方法(P<0.001)比 SS 更能成为阻碍远程卒中推广应用的障碍。然而,SS 认为增加个人工作量比 EP 更大(P<0.001)。
SS 和 EP 对远程卒中持积极看法;然而,实施仍存在障碍。需要解决 EP 和 SS 感知到的障碍之间的差异,以加强急性缺血性卒中的治疗。